Skip to main content
. 2017 Apr 27;12(4):e0176075. doi: 10.1371/journal.pone.0176075

Fig 3. Dose escalation study of 89Zr-GSK2849330 in CHL-1 xenograft tumor bearing mice as measured ex-vivo using a Gamma Counter at 72 hours.

Fig 3

Each group received a tracer dose (~0.14 mg/kg) of 89Zr-GSK2849330 plus a dose of non-labeled GSK2849330 (0, 0.3, 1, 3, or 10 mg/kg) (panels A and B). The normalized liver uptake to blood uptake ratio (Panel C) showed a significant decrease with the increased non labeled GSK2849330 (***p<0.01 vs 0 mg/kg; ##p<0.01, ###p<0.001 vs 0.3 mg/kg using One-way ANOVA). The normalized tumor uptake to blood uptake ratio (Panel D) showed a significant decrease with the increased non labeled GSK2849330 from 0.3 and 1 mg/kg compared to the 10 mg/kg group (#p<0.05 vs 1 mg/kg; ** p<0.01, *** p<0.001 vs 10 mg/kg using One-way ANOVA). Data is presented as mean±SEM (S2 Table).